367 related articles for article (PubMed ID: 27301022)
21. Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.
Pflégr V; Horváth L; Stolaříková J; Pál A; Korduláková J; Bősze S; Vinšová J; Krátký M
Eur J Med Chem; 2021 Nov; 223():113668. PubMed ID: 34198149
[TBL] [Abstract][Full Text] [Related]
22. Novel Hybrid 1,2,4- and 1,2,3-Triazoles Targeting Mycobacterium Tuberculosis Enoyl Acyl Carrier Protein Reductase (InhA): Design, Synthesis, and Molecular Docking.
El Sawy MA; Elshatanofy MM; El Kilany Y; Kandeel K; Elwakil BH; Hagar M; Aouad MR; Albelwi FF; Rezki N; Jaremko M; El Ashry ESH
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563096
[TBL] [Abstract][Full Text] [Related]
23. A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.
Perryman AL; Yu W; Wang X; Ekins S; Forli S; Li SG; Freundlich JS; Tonge PJ; Olson AJ
J Chem Inf Model; 2015 Mar; 55(3):645-59. PubMed ID: 25636146
[TBL] [Abstract][Full Text] [Related]
24. First triclosan-based macrocyclic inhibitors of InhA enzyme.
Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
[TBL] [Abstract][Full Text] [Related]
26. Function of heterologous Mycobacterium tuberculosis InhA, a type 2 fatty acid synthase enzyme involved in extending C20 fatty acids to C60-to-C90 mycolic acids, during de novo lipoic acid synthesis in Saccharomyces cerevisiae.
Gurvitz A; Hiltunen JK; Kastaniotis AJ
Appl Environ Microbiol; 2008 Aug; 74(16):5078-85. PubMed ID: 18552191
[TBL] [Abstract][Full Text] [Related]
27. Aqueous Molecular Dynamics Simulations of the M. tuberculosis Enoyl-ACP Reductase-NADH System and Its Complex with a Substrate Mimic or Diphenyl Ethers Inhibitors.
da Silva Lima CH; de Alencastro RB; Kaiser CR; de Souza MV; Rodrigues CR; Albuquerque MG
Int J Mol Sci; 2015 Oct; 16(10):23695-722. PubMed ID: 26457706
[TBL] [Abstract][Full Text] [Related]
28. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis.
He X; Alian A; Stroud R; Ortiz de Montellano PR
J Med Chem; 2006 Oct; 49(21):6308-23. PubMed ID: 17034137
[TBL] [Abstract][Full Text] [Related]
29. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery.
Prasad MS; Bhole RP; Khedekar PB; Chikhale RV
Bioorg Chem; 2021 Oct; 115():105242. PubMed ID: 34392175
[TBL] [Abstract][Full Text] [Related]
30. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
[TBL] [Abstract][Full Text] [Related]
31. A slow, tight binding inhibitor of InhA, the enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis.
Luckner SR; Liu N; am Ende CW; Tonge PJ; Kisker C
J Biol Chem; 2010 May; 285(19):14330-7. PubMed ID: 20200152
[TBL] [Abstract][Full Text] [Related]
32. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
[TBL] [Abstract][Full Text] [Related]
34. Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
Eur J Med Chem; 2014 Oct; 86():613-27. PubMed ID: 25218910
[TBL] [Abstract][Full Text] [Related]
35. Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities.
Schroeder EK; Basso LA; Santos DS; de Souza ON
Biophys J; 2005 Aug; 89(2):876-84. PubMed ID: 15908576
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and biological evaluation of phaitanthrin congeners as anti-mycobacterial agents.
Kamal A; Reddy BV; Sridevi B; Ravikumar A; Venkateswarlu A; Sravanthi G; Sridevi JP; Yogeeswari P; Sriram D
Bioorg Med Chem Lett; 2015 Sep; 25(18):3867-72. PubMed ID: 26253635
[TBL] [Abstract][Full Text] [Related]
37. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
[TBL] [Abstract][Full Text] [Related]
38. Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Alcaraz M; Sharma B; Roquet-Banères F; Conde C; Cochard T; Biet F; Kumar V; Kremer L
Eur J Med Chem; 2022 Sep; 239():114531. PubMed ID: 35759907
[TBL] [Abstract][Full Text] [Related]
39. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor.
Martínez-Hoyos M; Perez-Herran E; Gulten G; Encinas L; Álvarez-Gómez D; Alvarez E; Ferrer-Bazaga S; García-Pérez A; Ortega F; Angulo-Barturen I; Rullas-Trincado J; Blanco Ruano D; Torres P; Castañeda P; Huss S; Fernández Menéndez R; González Del Valle S; Ballell L; Barros D; Modha S; Dhar N; Signorino-Gelo F; McKinney JD; García-Bustos JF; Lavandera JL; Sacchettini JC; Jimenez MS; Martín-Casabona N; Castro-Pichel J; Mendoza-Losana A
EBioMedicine; 2016 Jun; 8():291-301. PubMed ID: 27428438
[TBL] [Abstract][Full Text] [Related]
40. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.
Holas O; Ondrejcek P; Dolezal M
J Enzyme Inhib Med Chem; 2015; 30(4):629-48. PubMed ID: 25383419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
